In a Phase III study, Eli Lilly’s Verzenio (abemaciclib) combined with standard adjuvant endocrine therapy met the trial’s primary endpoint of invasive disease-free survival in high-risk breast cancer and significantly reduced the risk of a recurrence of the disease.
With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.
There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.
Novartis’ Kisqali (ribociclib) won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients.
